By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Addex Therapeutics 

12, Chemin Des Aulx
1228 Plan-les-Ouates
Geneva      Switzerland
Phone: 41-22-884-1555 Fax: 41-22-884-1556




Company News
Addex Therapeutics (ADXN.SW) Amends mGlu2PAM Collaboration Agreement And Receives USD757,000 12/17/2014 9:43:18 AM
Addex Therapeutics (ADXN.SW) And The Charcot-Marie-Tooth Association Enter Collaboration To Advance ADX71441 In Charcot-Marie-Tooth 1A Disorder 10/21/2014 9:13:25 AM
Addex Therapeutics (ADXN.SW) Reports First Half 2014 Financial Results 9/30/2014 9:01:48 AM
Addex Therapeutics (ADXN.SW) ADX71441 Positive Results In Preclinical Model Of Nicotine Addiction 7/10/2014 6:06:33 AM
Addex Therapeutics (ADXN.SW) Shareholders Approve All Board Proposals At Annual General Meeting 6/30/2014 8:53:27 AM
Addex Therapeutics (ADXN.SW) Publishes Annual General Meeting Agenda 6/12/2014 2:05:54 PM
Addex Therapeutics (ADXN.SW)-Janssen Pharmaceutical Inc. Team's Depression Drug Fails In Phase 2a Trial 2/10/2014 7:32:27 AM
Addex Therapeutics (ADXN.SW) and National Institute on Drug Abuse (NIDA) Enter Collaboration to Advance ADX71441 & ADX88178 in Drug Abuse and Addiction 11/4/2013 9:39:09 AM
Addex Therapeutics (ADXN.SW) Licensee Completes Enrollment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression 10/29/2013 9:30:12 AM
Addex Therapeutics (ADXN.SW) ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease 10/3/2013 9:53:37 AM